TABLE 1.
Differences in clinical characteristics between the ES‐SCLC patients with chemo‐immunotherapy and chemotherapy as first line.
| Category and Sub‐category | Total patients (n = 353) | Chemo‐immune (n = 165) | Chemotherapy (n = 188) | p value |
|---|---|---|---|---|
| Age (year) mean ± SD | 62.40 ± 8.59 | 63.80 ± 8.83 | 61.26 ± 8.23 | 0.005** |
| Age (year), ≥65, n (%) | 163 (46.18) | 89 (53.94) | 74 (39.36) | 0.006** |
| Gender, Male, n (%) | 330 (93.48) | 151 (91.52) | 179 (95.21) | 0.113 |
| Smoking history, n (%) | 253 (71.67) | 105 (63.64) | 148 (78.72) | 0.002** |
| PS scores, 0–1, n (%) | 305 (86.40) | 137 (83.03) | 168 (89.36) | 0.083 |
| Location, Central, n (%) | 265 (75.07) | 121 (73.33) | 144 (76.60) | 0.480 |
| Metastatic sites, n (%) | ||||
| Intrapulmonary | 62 (17.56) | 39 (23.64) | 23 (12.23) | 0.005** |
| Liver | 94 (26.63) | 56 (33.94) | 38 (20.21) | 0.004** |
| Brain | 81 (22.95) | 56 (33.94) | 25 (13.30) | 0.761 |
| Bone | 107 (30.31) | 65 (39.39) | 42 (22.34) | 0.215 |
| Adrenal | 69 (19.55) | 50 (30.30) | 19 (10.11) | 0.001** |
| Distinct lymph nodes | 35 (9.92) | 16 (9.70) | 19 (10.11) | 0.898 |
| Pleura | 130 (36.83) | 66 (40.00) | 64 (34.04) | 0.437 |
| Other | 34 (9.63) | 15 (9.09) | 19 (10.11) | 0.247 |
| Anti‐vascular therapy, n (%) | 29 (8.22) | 15 (9.09) | 14 (7.45) | 0.575 |
| Thoracic radiotherapy, n (%) | 75 (21.25) | 39 (23.64) | 36 (19.15) | 0.318 |
| Brain radiotherapy, n (%) | 21 (5.95) | 11 (6.67) | 10 (5.32) | 0.593 |
| COPD, n (%) | 151 (42.78) | 70 (42.42) | 81 (43.09) | 0.900 |
| Interstitial pneumonia, n (%) | 15 (4.25) | 6 (3.64) | 9 (4.79) | 0.593 |
| Laboratory examination (median [IQR]) | ||||
| Neutrophil granulocyte | 5.20 (4.00, 6.90) | 5.40 (4.30, 6.90) | 5.10 (3.80, 6.90) | 0.102 |
| Lymphocyte | 1.60 (1.20, 2.00) | 1.60 (1.20, 2.00) |
1.60 (1.10, 2.00) |
0.340 |
| Eosinophils | 0.12 (0.10, 0.22) | 0.11 (0.10,0.26) | 0.12 (0.09, 0.20) | 0.430 |
| Platelet | 278.0 (220.8, 340.3) | 282.0 (224.0, 342.8) | 272.0 (208.8, 331.0) | 0.644 |
| Lactate dehydrogenase | 239.5 (193.8, 327.7) | 240.5 (201.8, 337.2) | 236.5 (179.5, 328.3) |
0.254 |
| Neuron specific enolase | 59.36 (31.96,117.85) | 64.42 (36.34, 112.20) | 51.97 (27.45,106.20) |
0.05 |
| Serum sodium | 137.00 (133.80, 139.40) | 137.65 (134.50,139.63) | 136.30 (132.65, 139.10) | 0.008** |
| IL‐2 | 1.39 (0.71, 1.97) | |||
| IL‐4 | 1.75 (0.96, 2.57) | |||
| IL‐6 | 8.84 (3.91, 19.34) | |||
| IL‐10 | 2.86 (2.13, 3.96) | |||
| TNF‐α | 1.62 (0.82, 3.03) | |||
| IFN‐γ | 1.49 (1.07, 2.35) |
Note: Range of normal values: Neutrophil granulocyte (1.8–8.0*109/L), Eosinophils (0.05–0.3*109/L), Lymphocyte (0.90–5.20*109/L), Platelet (100–400*109/L), Lactate dehydrogenase (109–225 U/L), Neuron specific enolase (0.00–16.3 ng/mL), serum sodium (135–145 mmol/L), IL‐2 (0–5.71 pg/mL), IL‐4 (0–2.8 pg/mL), IL‐6 (0–5.30 pg/mL), IL‐10 (0–4.91 pg/mL), TNF‐α (0–4.60 pg/mL), IFN‐γ (0–7.42 pg/mL).
Abbreviations: COPD, chronic obstructive pulmonary disease; ECOG PS, Eastern cooperative oncology group performance status; IQR, intra quartile range; SD, standard deviation.
**
p < 0.01.